Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Pharmaceutical industry news

Show

From To
How Will Generic Drugs Affect HIV Treatment in the U.S.?

In the U.S., in that many of the antiretroviral drugs that are commonly used today are approaching their patent expirations. So we can begin to conceptualize the use of generics in the U.S. and the potential cost savings. An Interview With Treatment Action Group's Tim Horn.

Published
31 October 2014
From
The Body
GSK eyes prime FTSE 100 slot for standalone HIV drugs business

GlaxoSmithKline, battered by weak U.S. drug sales and a bribery scandal in China, is looking to float ViiV, its fast-growing HIV drugs business as part of a recovery plan that includes a fresh round of cost cutting.

Published
26 October 2014
From
Reuters
GlaxoSmithKline weighs an IPO for HIV-focused ViiV as it sharpens the budget axe

In the preamble to GSK's latest earnings statement, CEO Andrew Witty heralded the progress of ViiV, majority-owned by his company, since its foundation 5 years ago. Now, as ViiV enters the commercialization phase and continues building its pipeline, it might benefit from access to public markets, according to Witty. What that might mean in specific terms remains up in the air, and it's unclear whether GSK is considering selling off shares of only its own stake in the business.

Published
22 October 2014
From
FierceBiotech
Juncker seen making U-turn on medicines policy

Jean-Claude Juncker has ceded to pressure from MEPs and abandoned his plan to return control of medicines and pharmaceutical products to the Industry Commissioner. This responsibility will instead remain in the hands of the Health Commissioner.

Published
17 October 2014
From
EurActiv
Unique 'pay if you clear' proposal for new hepatitis drug

The NHS in Scotland could be reimbursed for the cost of a new hepatitis drug if sufferers fail to clear the virus. The novel proposal was revealed after the drug Olysio was cleared for use by the Scottish Medicines Consortium (SMC).

Published
15 October 2014
From
BBC
Fair Pricing Coalition Urges a Uniform Price for Curative Hepatitis C Treatment

The $63,000 wholesale acquisition cost (WAC) for eight weeks of Harvoni™ (sofosbuvir and ledipasvir) should be extended to 12 and 24-week curative treatment durations.

Published
15 October 2014
From
Fair Pricing Coalition
If AbbVie Discounts its Hep C Drug, Would Pricing Reach a Tipping Point?

Now that the FDA has approved the Harvoni treatment from Gilead Sciences and a $94,500 price for a 12-week regimen has been established, attention is turning toward AbbVie and the steps the big drug maker must take to win market share. Already, though, some Wall Street prognosticators believe AbbVie may find it daunting.

Published
15 October 2014
From
Wall Street Journal
In a surprise move, Bristol-Myers drops U.S. approval plans for hep C drug

After sizing up the competitive landscape as rival Gilead ($GILD) races ahead with a new combo treatment, Bristol-Myers has opted to drop its application to gain an approval in the U.S. for asunaprevir, its NS3/4A protease inhibitor, and won't go after an OK to use a combination of daclatasvir and asunaprevir for genotype 1b patients.

Published
07 October 2014
From
Fierce Biotech
Europe: Pharma industry denies it lobbied for medicines to move to DG Enterprise

Europe’s pharmaceutical industry has said it did not lobby for medicines and medical devices to be moved from the European Commission's health directorate (DG Sanco) to the enterprise directorate (DG Enterprise).

Published
01 October 2014
From
EurActiv
J&J makes a splash in hep C with a $1.75B deal for Alios

Johnson & Johnson ($JNJ) is taking a deep dive into antivirals, trading $1.75 billion for private biotech Alios BioPharma to get its hands on a midstage treatment and some early assets that could expand its share of the blockbuster hepatitis C market.

Published
01 October 2014
From
Fierce Biotech
← First12345...69Next →

Filter by country